According to Ukraine, Russia fired the first ICBM ever used in warfare at the Ukrainian city of Dnipro . Two people were injured by the conventional warhead. The missile was part of a barrage of various types of missiles including hypersonic missiles. Other sources say it was an intermediate-range ballistic missile, which is a sort of scaled-down ICBM with a shorter range. The attack comes after the US approved the use of long-range ATACMS missiles by Ukraine for strikes inside Russia. The attack also came with a lot of rhetoric attached. Russia has now “updated” its nuclear doctrine to state that any non-nuclear power acting in partnership with a nuclear power is to be considered a “joint attack”. This is more or less standard Russian dogma, emphasizing its nuclear capabilities. There is no comparison between an ATACMS missile and any sort of nuclear weapon . Russia’s military situation in Ukraine is now such a total failure that rhetoric makes far more headlines than actual military achievements. Most of their “advances” in Donetsk are minuscule, taking back what they claim to be their own territory. In an additional escalation, this time a real one, North Korean troops and weapons are said to be operating in Russia . Various sources state these troops are operating in the Kursk region and taking significant casualties. They don’t seem to be particularly combat-effective. Despite claims by the incoming Trump administration, this situation is likely to be difficult to defuse. Russia is trying to save face. Its military has take a severe beating for nearly three years. Ukraine won’t back down. Ukraine has nothing to gain from a pseudo-peace which may simply turn into another attack after the Russian military has regrown itself. A lasting peace is beyond US capabilities to deliver. The big loser in a failed peace deal would be the US. America would simply look weak and naïve, and in many ways simply stupid. It would also look as though the US was trying to save Russia, which is the exact opposite of saving face for Putin. The highly skeptical rest of the world wouldn’t be impressed. It’s the wrong message to send to this planet’s other 8 billion people. Trump has a unique ability to damage America’s reputation and credibility in a few sentences. He spent most of his first term annoying America’s allies making baseless statements about them. He’s not seen as a “strong leader” outside the US. He’s seen as a highly personally compromised figurehead at best and chronically incompetent on average. He certainly can’t even pretend to lead the rest of the world social media propaganda notwithstanding. That’s a big shift in the wrong direction. America was in fact a leader of the free world. Under Trump, it’s likely to be purely antagonistic and entirely insular, with no trust. Add to this self-inflicted mess the various other messages about tariffs, deportations, and democracy in general, and the US could lose just about all of the goodwill of the last century in a month or so. The winner would be China. In comparison to a tariff-addled, backward-looking, fact-ignoring America and a crippled Russia, China can only look good. Nothing can save Russia from the consequences of this idiotic self-inflicted war. Europe is rearming. China can pull the plug whenever it wants. It’s game over in so many ways. America can only be “great” by enforcing a just and permanent peace. Let’s see who the vertebrates are in this scenario. Editor-at-Large based in Sydney, Australia.
On Nov. 21, shares of CRISPR Therapeutics ( CRSP 3.44% ) were down 47% from a peak they reached in March. This might be a little surprising to folks who have been following this developer of gene therapies. After all, it's been less than a year since regulators in the U.S. and E.U. approved its first therapy, Casgevy, to treat two blood-based disorders. Casgevy's initial launch hasn't been as exciting as investors and its partner, Vertex Pharmaceuticals ( VRTX 0.13% ) , had hoped. Less than a year into the launch, though, it's still too early to turn our backs on this innovative drugmaker. After all, in addition to Casgevy, it has five other therapy candidates in clinical-stage testing. To see if adding some shares to your portfolio now makes sense, let's look at why the stock's been beaten down, and what could lift it back up. Why CRISPR Therapeutics stock is down The Food and Drug Administration (FDA) approved Casgevy for the treatment of sickle cell disease (SCD) last December. In January the agency followed up with approval to treat transfusion-dependent beta thalassemia (TDT). Across the Atlantic, European regulators approved Casgevy to treat both SCD and TDT in February. Despite regulatory approvals, the launch is progressing more slowly than investors had expected. CRISPR Therapeutics wisely partnered with Vertex Pharmaceuticals to develop and market Casgevy, but Vertex is having a hard time getting it off the ground. Despite earning approval in late 2023, Vertex didn't record its first sale of Casgevy until the third quarter. Sales have been slow because it's a complicated therapy made in single batches from a patient's stem cells. Once reinfused, the CRISPR-altered stem cells should produce functioning hemoglobin, so SCD and TDT patients no longer need regular blood transfusions. Unfortunately, reinfused Casgevy cells can't gain a foothold unless patients first deplete their immune systems with a dangerous conditioning regimen. Recently, a patient with SCD died during a gene-therapy trial run by Beam Therapeutics . Physicians running the study didn't fault Beam's candidate for the volunteer's death; they blamed a conditioning regimen containing busulfan. Busulfan is also used to condition patients for Casgevy. Reasons to buy CRISPR Therapeutics stock right now A lack of treatment options could work in Casgevy's favor. Last year, the European Medicines Agency revoked conditional approval for an SCD drug from Novartis called Adakveo, after it failed to outperform a placebo in a confirmatory trial. And in September, Pfizer pulled Oxbryta, a daily tablet approved to treat SCD patients, from the market after it failed a postmarketing study. At the end of September, Vertex Pharmaceuticals and CRISPR Therapeutics had infused just one patient with Casgevy, but more are on the way. As of mid-October, authorized treatment centers had already collected stem cells from 40 patients. With a list price of $2.2 million, reaching tiny slivers of the SCD and TDT populations could drive annual sales above $1 billion. Five candidates in clinical-stage testing mean Casgevy probably won't be the last FDA-approved therapy to emerge from CRISPR Therapeutics' pipeline. At the upcoming American Society of Hematology meeting in December, the company will present phase 1 trial results for CTX112, an experimental blood-cancer treatment that could be next to reach the commercial stage. We already know CTX112 shrank tumors for six out of nine advanced-stage lymphoma patients. Four of them achieved complete remission. These results would be impressive for a population of relatively healthy patients who just received their first cancer diagnosis, but this group was heavily pretreated. A buy now? With a lack of Casgevy revenue to date, CRISPR Therapeutics is still losing money. Thanks to its partnership with Vertex, though, the losses are manageable. It came up short by just $85.9 million during the third quarter. The company finished September with $1.9 billion in cash. A big cash pile gives CRISPR Therapeutics a long runway to ramp up sales of Casgevy. It also gives CTX112 and the rest of the pipeline time to shine before the company needs to raise capital with a dilutive secondary offering. CRISPR Therapeutics has a $3.9 billion market cap at recent prices, but the stock is less expensive than it looks on the surface. With a big cash cushion and a lack of debt, its enterprise value is just $2.1 billion at recent prices. That's not an unreasonable price to pay for a commercial-stage drugmaker with a handful of new candidates in clinical trials. The stock valuation isn't entirely unreasonable, but it's still high enough to make it a very risky investment. If Casgevy sales don't ramp up soon, or the clinical-stage pipeline falters, investors who buy at recent prices could suffer heavy losses. Unless you have a very high risk tolerance, it's best to keep your distance from CRISPR Therapeutics stock.
15 SpyLoan Apps Found on Play Store Targeting Millions
LOS ANGELES — UCLA football underclassmen carried their seniors off the field after Thursday’s practice as part of Bruin tradition, hoisting them above their shoulders in honor of the work they’ve done in their time with the team. Two days later, 42 players walked in the Senior Day celebration prior to the Bruins’ season finale against Fresno State at the Rose Bowl. Redshirt junior Carson Schwesinger took part in the celebration, indicating the possibility that the Butkus Award-nominated linebacker may not stay for another next season. Schwesinger and head coach DeShaun Foster said the FBS’ leading tackler has not made a decision as to whether he will go to the NFL. “He’s really going to do whatever is best for him in that situation,” Foster told reporters Wednesday. “I completely understand, especially if he gets the Butkus Award, and the way that he came out and performed this season. He deserves to get a shot and go to the NFL.” Receiver J.Michael Sturdivant also walked for Senior Day. Sturdivant, a redshirt junior, was UCLA’s third-leading receiver heading into Saturday’s game with 311 total yards and one touchdown. He averaged 31.1 yards per game. Sturdivant’s ability to stretch the field was underutilized in his two seasons at UCLA after he previously played two seasons at Cal. Offensive lineman Josh Carlin, edge rusher Oluwafemi Oladejo and defensive lineman Jay Toia each walked with the seniors Saturday and are expected to make a push for the NFL. “Incredibly grateful for the Bruin program, the UCLA program,” Oladejo told reporters Tuesday. “Came in here at the age of 19 and I’m now 21, so I’ve grown here a lot. Grown as a man, matured. Not just on the field but off the field as well. This means a lot to me.” Other notable players who took part in Senior Day: offensive lineman Garret DiGiorgio, quarterbacks Ethan Garbers and Chase Griffin, running back Keegan Jones, receiver Logan Loya, tight end Moliki Matavao and linebacker Kain Medrano. “A game like, this you want to send the seniors off on the right note,” Schwesinger said, “but on top of that, it’s being able to go out there and play competitively. We’re all here because we like to play football and you get a chance to do that, you’ve gotta go out and play your hardest.” Olympic and UCLA gymnast Jordan Chiles was in attendance for Saturday’s football game and gave a “4’s up” gesture on the big screen during the second quarter, promoting her return to UCLA. Chiles, a junior who took a year off to train for and compete in the 2024 Paris Olympics, will make her return as a Bruin for the upcoming 2025 season. She made the announcement in an interview with TODAY’s Hoda Kotb in early August. Related Articles Chiles won a silver medal in 2020 to make her the most decorated Olympian in UCLA women’s gymnastics history. She scored three perfect 10s in her 2022 season as a Bruin — two in floor exercise and one on the uneven bars. She won NCAA titles in both events in 2023 and was the runner-up in the all-around at the national championships. UCLA’s gymnastics season begins with its Meet the Bruins event on Dec. 14 at Pauley Pavilion.
McCormick & Co. Inc. stock falls Tuesday, underperforms marketPathstone Holdings LLC reduced its position in Public Service Enterprise Group Incorporated ( NYSE:PEG – Free Report ) by 0.3% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 49,806 shares of the utilities provider’s stock after selling 173 shares during the period. Pathstone Holdings LLC’s holdings in Public Service Enterprise Group were worth $4,443,000 at the end of the most recent reporting period. Several other institutional investors also recently bought and sold shares of PEG. Raymond James & Associates boosted its holdings in shares of Public Service Enterprise Group by 315.2% during the second quarter. Raymond James & Associates now owns 2,206,101 shares of the utilities provider’s stock worth $162,590,000 after purchasing an additional 1,674,827 shares during the last quarter. Sound Shore Management Inc. CT acquired a new stake in Public Service Enterprise Group in the 2nd quarter worth about $71,298,000. Hsbc Holdings PLC boosted its stake in Public Service Enterprise Group by 43.2% in the 2nd quarter. Hsbc Holdings PLC now owns 2,426,170 shares of the utilities provider’s stock worth $178,763,000 after buying an additional 732,443 shares during the last quarter. Raymond James Financial Services Advisors Inc. grew its holdings in Public Service Enterprise Group by 381.7% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 800,848 shares of the utilities provider’s stock valued at $59,023,000 after buying an additional 634,587 shares during the period. Finally, Zurich Insurance Group Ltd FI acquired a new position in shares of Public Service Enterprise Group during the 1st quarter valued at about $28,132,000. 73.34% of the stock is currently owned by institutional investors and hedge funds. Wall Street Analyst Weigh In A number of research firms recently issued reports on PEG. Barclays lowered their target price on shares of Public Service Enterprise Group from $98.00 to $88.00 and set an “overweight” rating for the company in a report on Tuesday, November 5th. BMO Capital Markets upped their price objective on Public Service Enterprise Group from $86.00 to $89.00 and gave the stock a “market perform” rating in a report on Monday, October 21st. UBS Group boosted their price target on Public Service Enterprise Group from $94.00 to $98.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. Evercore ISI lifted their price objective on Public Service Enterprise Group from $92.00 to $95.00 and gave the company an “outperform” rating in a research note on Tuesday, October 8th. Finally, Jefferies Financial Group started coverage on Public Service Enterprise Group in a report on Friday, September 13th. They set a “hold” rating and a $85.00 target price for the company. Four investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Public Service Enterprise Group has an average rating of “Moderate Buy” and an average target price of $86.69. Public Service Enterprise Group Price Performance Shares of PEG stock opened at $92.40 on Friday. The firm has a fifty day simple moving average of $88.38 and a 200-day simple moving average of $80.67. The company has a market capitalization of $46.04 billion, a PE ratio of 22.70, a price-to-earnings-growth ratio of 3.39 and a beta of 0.61. Public Service Enterprise Group Incorporated has a twelve month low of $56.85 and a twelve month high of $93.00. The company has a current ratio of 0.68, a quick ratio of 0.48 and a debt-to-equity ratio of 1.18. Public Service Enterprise Group ( NYSE:PEG – Get Free Report ) last posted its quarterly earnings data on Monday, November 4th. The utilities provider reported $0.90 earnings per share for the quarter, beating analysts’ consensus estimates of $0.87 by $0.03. Public Service Enterprise Group had a net margin of 19.48% and a return on equity of 10.70%. The company had revenue of $2.64 billion during the quarter, compared to analysts’ expectations of $2.44 billion. During the same period in the prior year, the company posted $0.85 EPS. The firm’s revenue for the quarter was up 7.6% on a year-over-year basis. Equities research analysts anticipate that Public Service Enterprise Group Incorporated will post 3.66 earnings per share for the current fiscal year. Public Service Enterprise Group Announces Dividend The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 31st. Shareholders of record on Tuesday, December 10th will be issued a dividend of $0.60 per share. The ex-dividend date is Tuesday, December 10th. This represents a $2.40 annualized dividend and a yield of 2.60%. Public Service Enterprise Group’s dividend payout ratio is presently 58.97%. Insider Buying and Selling at Public Service Enterprise Group In other news, EVP Tamara Louise Linde sold 9,563 shares of the business’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $79.54, for a total value of $760,641.02. Following the completion of the sale, the executive vice president now owns 57,961 shares of the company’s stock, valued at approximately $4,610,217.94. The trade was a 14.16 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website . Also, SVP Richard T. Thigpen sold 5,900 shares of the stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $87.95, for a total transaction of $518,905.00. Following the transaction, the senior vice president now directly owns 25,829 shares in the company, valued at $2,271,660.55. The trade was a 18.59 % decrease in their position. The disclosure for this sale can be found here . Insiders have sold a total of 28,739 shares of company stock valued at $2,467,753 in the last three months. Corporate insiders own 0.57% of the company’s stock. Public Service Enterprise Group Company Profile ( Free Report ) Public Service Enterprise Group Incorporated, through its subsidiaries, operates in electric and gas utility business in the United States. It operates through PSE&G and PSEG Power segments. The PSE&G segment transmits electricity; distributes electricity and natural gas to residential, commercial, and industrial customers; and appliance services and repairs to customers through its service territory, as well as invests in solar generation projects, and energy efficiency and related programs. Featured Articles Want to see what other hedge funds are holding PEG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Public Service Enterprise Group Incorporated ( NYSE:PEG – Free Report ). Receive News & Ratings for Public Service Enterprise Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Public Service Enterprise Group and related companies with MarketBeat.com's FREE daily email newsletter .
FNA DEADLINE NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Paragon 28, Inc. Investors ...
Eagles WR DeVonta Smith (hamstring) ruled out vs. RamsDejan Kulusevski cannot wait for the opportunity to play against Manchester City again after Tottenham ran riot at the Etihad Stadium. The Sweden midfielder hailed Saturday’s 4-0 thrashing of the champions as the best game of his career. The 24-year-old delivered an outstanding performance as Spurs shattered the champions’ 52-game unbeaten home run, helping start the rout with a superb cross for James Maddison’s opening goal. Kulusevski said: “I believed (we would win) this because in the past years, we’ve come here and played really well. “So this is the game I look forward to most in the year and, once again, it happened – glory to God. “I’d say it’s the best result ever in my career. It’s a big night for the whole club, for the coach, for the players. “Because City have a lot of the ball sometimes, we can rest when we defend. There’s also so much space up there, we play one against one and then it’s always dangerous because we have a lot of quality. “It’s always great to play great teams because they always want to play football. When you play lower teams, sometimes it’s not. There’s not much football played because they are a lot of fouls, a lot of injuries and it’s slow going.” Maddison stole the show with two goals in quick succession in the first half while Pedro Porro and Brennan Johnson later got on the scoresheet. Yet Kulusevski’s performance was also eye-catching and the player himself believes there is plenty more to come from him. Asked if his form made him feel “unstoppable”, Kulusevski said: “I feel like that. I feel very good and I’m trying to keep this way. I’m very happy, I’m trying to improve. “I started the season good but there is over half of the season left and I hope I can do much better. “I think I have something that no other player has. With my engine, with my heart – I don’t get tired – I feel like I can do a lot still in my career.” Tottenham’s scintillating performance marked a spectacular return to form after their dismal loss to Ipswich in their previous Premier League outing. Kulusevski said: “We have to be much more consistent. It’s not a turning point. We just have to be better in other games. “This game suited us perfectly but we have a lot of improvement to make in the other games.”
Next big thing declares he’s ready for Test debutBUCHAREST, Romania (AP) — A far-right populist took the lead in Romania’s presidential election Sunday, electoral data showed, and will likely face leftist Prime Minister Marcel Ciolacu in a runoff in two weeks, an outcome that rocked the country's political landscape. Calin Georgescu, who ran independently, led the polls with around 22% of the vote, while Ciolacu of the Social Democratic Party, or PSD, trailed at 20.6%. Elena Lasconi of the Save Romania Union party, or USR, stood at about 17.4%, and George Simion, the leader of the far-right Alliance for the Unity of Romanians, or AUR, took 14.3%. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.
St. Bonaventure’s Noel Brown becoming center of attention as Bonnies move to 6-0